|
May 15
|
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
|
|
May 13
|
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
|
|
May 12
|
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
|
|
Apr 16
|
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
|
|
Apr 16
|
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
|
|
Feb 17
|
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
|
|
Jul 25
|
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
|
|
Jun 18
|
Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024
|
|
Jan 12
|
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
|
|
Dec 19
|
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
|
|
Dec 10
|
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
|
|
Nov 27
|
Innate Pharma to Host Virtual KOL Event on Lacutamab
|
|
Nov 7
|
Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update
|
|
Jul 11
|
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
|
|
Jul 7
|
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
|